The prognostic value of interleukin-6 in the assessment of arrhythmia recurrence in patients with hypertension and paroxysmal atrial fibrillation
Open Access
- 10 October 2026
- journal article
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (9) , 518-523
Abstract
Aim. To study the prognostic value of interleukin-6 (IL-6) in assessing the risk of arrhythmia recurrence in patients with arterial hypertension (AH) and paroxysmal atrial fibrillation (AF). Materials and methods. 95 patients with AH and paroxysmal AF were included in the study. The prospective follow-up of the patients was 6 months, and the end point of the study was a reported recurrence of AF. Depending on the end point of the study, the patients were divided into 2 groups: group 1 included 32 patients who had a recurrence of AF within 6 months; group 2 consisted of 63 patients without recurrence of arrhythmia. Results. The average concentration of IL-6 in blood plasma at the inclusion visit was significantly higher in patients of group 1 than in patients of group 2 (p0.05). There was a significant increase in the Cardio-Ankle Vascular Index (CAVI index) in patients with AF relapses than in patients without AF relapses – 8.9 [8.6; 9.1] and 7.7 [7.5; 8.3] (p0.05). We found a moderate direct correlation between the value of the CAVI index and the plasma concentration of IL-6 (r=0.6; p=0.024). In patients with AH and paroxysmal AF, a statistically significant association with the likelihood of arrhythmia recurrence was shown by such indicators as the level of IL-6 in blood plasma (Odds Ratio 1.42, 95% Confidence Interval – CI 1.18–1.70; p=0.001) and the CAVI index (Odds Ratio 1.31, 95% CI 1.08–1.58; p=0.005). Conclusion. An increase in the level of IL-6 in blood plasma of more than 4.0 pg/ml with a sensitivity of 70% and specificity of 72% indicates a high risk of AF recurrence in patients with AH and paroxysmal AF (Area Under the Curve – AUC 0.76), increases the risk of recurrence of arrhythmia by 1.42 times (95% CI 1.18–1.70; p=0.001).Keywords
This publication has 12 references indexed in Scilit:
- Interleukin-6: Molecular Mechanisms and Therapeutic Perspectives in Atrial FibrillationCurrent Medical Science, 2025
- 2024 Clinical practice guidelines for Hypertension in adultsRussian Journal of Cardiology, 2024
- Dynamic biomarker profiles in patients with paroxysmal atrial fibrillation: Assessing the differences between sinus rhythm and acute atrial fibrillation episodeInternational Journal of Cardiology, 2024
- Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trialsJournal of Thrombosis and Haemostasis, 2020
- The Clinical Significance of Interleukin-6 in Heart Failure: Results from the BIOSTAT-CHF StudyEuropean Journal of Heart Failure, 2019
- Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesisAmerican Journal of Physiology-Cell Physiology, 2018
- The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillationCytokine, 2018
- Role of Inflammation in Atrial Fibrillation Pathophysiology and ManagementCirculation Journal, 2015
- Relationship of interleukin-6 and C-Reactive protein to the prothrombotic state in chronic atrial fibrillationJACC, 2004
- Interleukin-6 Exacerbates Early Atherosclerosis in MiceArteriosclerosis, Thrombosis, and Vascular Biology, 1999